Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous lidocaine dose-ranging trial for persistent post-traumatic or post-surgical peripheral neuropathic pain
ACTRN12622000538741Phase 3Completed
- Sponsor
- Royal Brisbane and Women's Hospital
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lidocaine in Peripheral neuropathic pain (3 arms), sponsored by Royal Brisbane and Women's Hospital. Primary endpoints: Effective analgesia and Serious adverse events requiring infusion cessation or contraindicating future lidocaine infusion. Started Dec 2022; status: completed.
02
Drugs
lidocaine
03
Conditions
Peripheral neuropathic pain
Beyond the preview
Go deeper on ACTRN12622000538741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000538741.